These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 8879975)

  • 1. Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge.
    Chilvers CE
    Drug Saf; 1996 Sep; 15(3):212-8. PubMed ID: 8879975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
    Kaunitz AM
    J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Thomas DB; Noonan L; Whitehead A
    Bull World Health Organ; 1985; 63(3):513-9. PubMed ID: 2931206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot medroxyprogesterone acetate and breast cancer. A pooled analysis of the World Health Organization and New Zealand studies.
    Skegg DC; Noonan EA; Paul C; Spears GF; Meirik O; Thomas DB
    JAMA; 1995 Mar; 273(10):799-804. PubMed ID: 7861575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Lancet; 1991 Oct; 338(8771):833-8. PubMed ID: 1681212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The contraceptive use of depot medroxyprogesterone acetate.
    Hickey M; Fraser I
    Clin Obstet Gynecol; 1995 Dec; 38(4):849-58. PubMed ID: 8616981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?
    Rosenfield A; Maine D; Rochat R; Shelton J; Hatcher RA
    JAMA; 1983 Jun; 249(21):2922-8. PubMed ID: 6221125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica.
    Oberle MW; Rosero-Bixby L; Irwin KL; Fortney JA; Lee NC; Whatley AS; Bonhomme MG
    Int J Epidemiol; 1988 Dec; 17(4):718-23. PubMed ID: 2976059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone density in long term users of depot medroxyprogesterone acetate.
    Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
    Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of depo-medroxyprogesterone acetate and breast cancer.
    Greenspan AR; Hatcher RA; Moore M; Rosenberg MJ; Ory HW
    Contraception; 1980 Jun; 21(6):563-9. PubMed ID: 7428364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
    Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
    Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer and depot-medroxyprogesterone acetate: a review.
    Chilvers C
    Contraception; 1994 Mar; 49(3):211-22. PubMed ID: 8200215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation.
    Pardthaisong T; Yenchit C; Gray R
    Contraception; 1992 Apr; 45(4):313-24. PubMed ID: 1387602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term depot-medroxyprogesterone acetate and bone mineral density.
    Tang OS; Tang G; Yip P; Li B; Fan S
    Contraception; 1999 Jan; 59(1):25-9. PubMed ID: 10342083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasive cervical cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
    Thomas DB; Noonan L; Whitehead A; Roseman D
    Bull World Health Organ; 1985; 63(3):505-11. PubMed ID: 2931205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depot medroxyprogesterone. Management of side-effects commonly associated with its contraceptive use.
    Archer B; Irwin D; Jensen K; Johnson ME; Rorie J
    J Nurse Midwifery; 1997; 42(2):104-11. PubMed ID: 9107118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.